國家衛生研究院 NHRI:Item 3990099045/13067

NHRI > National Institute of Infectious Diseases and Vaccinology > Tsai-Ling Yang Lauderdale > Periodical Articles > Item 3990099045/13067

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13067

Title:	Serotype distribution and antimicrobial susceptibility of streptococcus pneumoniae in pre-and post- PCV7/13 Eras, Taiwan, 2002–2018
Authors:	Wu, CJ;Lai, JF;Huang, IW;Shiau, YR;Wang, HY;Lauderdale, TL
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	In Taiwan, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2006 and a PCV13 national childhood catchup program was implemented in 2013. To delineate the trend of serotype distribution and antimicrobial susceptibility following vaccination programs, we investigated a total of 1845 Streptococcus pneumoniae isolates collected biennially between 2002 and 2018 over a 3-month period from 25 hospitals. The number of isolates collected over the years decreased significantly in all age groups, from a total of 320 isolates in 2002 (pre-PCV), to 196 in 2010 (post-PCV7/pre-PCV13), to 89 in 2018 (post-PCV13). Overall, PCV7/PCV13 serotypes comprised 66.9%/76.3%, 53.1%/78.1%, and 15.7%/31.5% of isolates in 2002, 2010, and 2018, respectively. The leading serotypes in the pre-PCV era were 23F, 19F, 6B, and 14, while serotype 19A predominated in the post-PCV7/pre-PCV13 era, but non-vaccine serotypes (NVT) 15A (18.0%) and 23A (15.7%) surpassed 19A (10.1%) to become the top two leading serotypes in 2018. All the major serotypes, including the emergent serotypes 15A and 23A, were multidrug-resistant with high rates of non-susceptibility to β-lactam (except serotype 3) and several non-β-lactam agents. PFGE and MLST revealed that while meropenem-susceptible serotype 15A-ST3058 isolates and a serotype 23A-ST338 clone existed in earlier years, rise and spread of meropenem-non-susceptible serotype 15A-ST63 and serotype 23A-ST166 clones occurred in recent years. We conclude that successive implementation of PCVs has led to a marked decrease in pneumococcal isolate burden, but the replacement by meropenem-non-susceptible NVT 15A and 23A highlights the need for continued local surveillance to track pneumococcal evolution in each region to help vaccine polyvalency decisions.
Date:	2020-10-22
Relation:	Frontiers in Microbiology. 2020 Oct 22;11:Article number 557404.
Link to:	http://dx.doi.org/10.3389/fmicb.2020.557404
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1664-302X&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000585393900001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85095711737
Appears in Collections:	[Tsai-Ling Yang Lauderdale] Periodical Articles [Chi-Jung Wu] Periodical Articles

Files in This Item:

File	Size	Format
SCP85095711737.pdf	1785Kb	Adobe PDF	393	View/Open

Loading...